Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 1, 2016, Pages E71-E80

  Nishio, Miki ^a   Sugimachi, Keishi ^b   Goto, Hiroki ^a   Wang, Jia ^a   Morikawa, Takumi ^a   Miyachi, Yosuke ^a   Takano, Yusuke ^a   Hikasa, Hiroki ^a   Itoh, Tohru ^c   Suzuki, Satoshi O ^a   Kurihara, Hiroki ^d   Aishima, Shinichi ^e   Leask, Andrew ^f   Sasaki, Takehiko ^g   Nakano, Toru ^h   Nishina, Hiroshi ⁱ   Nishikawa, Yuji ^j   Sekido, Yoshitaka ^k   Nakao, Kazuwa ^l   Shin Ya, Kazuo ^m   Mimori, Koshi ^b   Suzuki, Akira ^a   more..

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY BEPPU HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e SAGA UNIVERSITY   (Japan)

^f WESTERN UNIVERSITY   (Canada)

^g AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h OSAKA UNIVERSITY   (Japan)

ⁱ TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^j ASAHIKAWA MEDICAL COLLEGE   (Japan)

^k AICHI CANCER CENTER HOSPITAL   (Japan)

^l KYOTO UNIVERSITY   (Japan)

^m NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

more..

Author keywords

Hippo pathway; Ivermectin; Liver cancer; MOB1; TGF beta

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; LACTONE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TAZ; TRANSCRIPTION FACTOR YAP1; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; MOB1 PROTEIN, MOUSE; MOB1B PROTEIN, MOUSE; PHOSPHOPROTEIN; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TAZ PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA2.3; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HEPATOMEGALY; HYPERPLASIA; LIVER CARCINOGENESIS; LIVER CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; BILE DUCT CARCINOMA; BILE DUCT TUMOR; CARCINOGENESIS; DRUG SCREENING; GENETICS; HUMAN; KNOCKOUT MOUSE; LIVER; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BILE DUCT NEOPLASMS; CARCINOGENESIS; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; CONNECTIVE TISSUE GROWTH FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENES, TUMOR SUPPRESSOR; HUMANS; HYPERPLASIA; LIVER; LIVER NEOPLASMS; MICE; MICE, KNOCKOUT; MICE, NUDE; PHOSPHOPROTEINS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84953230626     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1517188113     Document Type: Article

References (64)

1. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362(9399): 1907-1917.
2. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94(2):153-156.
3. Anonymous (1992) Prevention and control of neurofibromatosis: Memorandum from a joint WHO/NNFF meeting. Bull World Health Organ 70(2):173-182.
4. Edgar BA (2006) From cell structure to transcription: Hippo forges a new path. Cell 124(2):267-273.
5. Hergovich A (2011) MOB control: Reviewing a conserved family of kinase regulators. Cell Signal 23(9):1433-1440.
6. Nishio M, Otsubo K, Maehama T, Mimori K, Suzuki A (2013) Capturing the mammalian Hippo: Elucidating its role in cancer. Cancer Sci 104(10):1271-1277.
7. Dupont S, et al. (2011) Role of YAP/TAZ in mechanotransduction. Nature 474(7350): 179-183.
8. Kanai F, et al. (2000) TAZ: A novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 19(24):6778-6791.
9. Zhao B, et al. (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22(14):1962-1971.
10. Anakk S, et al. (2013) Bile acids activate YAP to promote liver carcinogenesis. Cell Reports 5(4):1060-1069.
11. Yi C, et al. (2013) The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. Sci Signal 6(291):ra77.
12. Tschaharganeh DF, et al. (2013) Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology 144(7):1530-1542.e1512.
13. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL (2010) A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev 24(1):72-85.
14. Benhamouche S, et al. (2010) Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev 24(16):1718-1730.
15. Lu L, et al. (2010) Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA 107(4):1437-1442.
16. Lee JH, et al. (2008) A crucial role of WW45 in developing epithelial tissues in the mouse. EMBO J 27(8):1231-1242.
17. Zhou D, et al. (2009) Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16(5):425-438.
18. Song H, et al. (2010) Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci USA 107(4):1431-1436.
19. Zender L, et al. (2006) Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125(7):1253-1267.
20. Camargo FD, et al. (2007) YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 17(23):2054-2060.
21. Dong J, et al. (2007) Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130(6):1120-1133.
22. Yimlamai D, et al. (2014) Hippo pathway activity influences liver cell fate. Cell 157(6): 1324-1338.
23. Zhang N, et al. (2010) The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 19(1):27-38.
24. Schlegelmilch K, et al. (2011) Yap1 acts downstream of α-catenin to control epidermal proliferation. Cell 144(5):782-795.
25. Stavridi ES, et al. (2003) Crystal structure of a human Mob1 protein: toward understanding Mob-regulated cell cycle pathways. Structure 11(9):1163-1170.
26. Lignitto L, et al. (2013) Proteolysis of MOB1 by the ubiquitin ligase praja2 attenuates Hippo signalling and supports glioblastoma growth. Nat Commun 4:1822.
27. Kosaka Y, et al. (2007) Clinical significance of the loss of MATS1 mRNA expression in colorectal cancer. Int J Oncol 31(2):333-338.
28. Nishio M, et al. (2012) Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice. J Clin Invest 122(12):4505-4518.
29. Xu MZ, et al. (2009) Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115(19):4576-4585.
30. Ikushima H, Miyazono K (2010) TGFbeta signalling: A complex web in cancer progression. Nat Rev Cancer 10(6):415-424.
31. Bierie B, Moses HL (2006) Tumour microenvironment: TGFbeta: The molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6(7):506-520.
32. Kitisin K, et al. (2007) Tgf-Beta signaling in development. Sci STKE 2007(399):cm1.
33. Varelas X, et al. (2008) TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol 10(7):837-848.
34. Varelas X, et al. (2010) The Crumbs complex couples cell density sensing to Hippodependent control of the TGF-β-SMAD pathway. Dev Cell 19(6):831-844.
35. Postic C, Magnuson MA (2000) DNA excision in liver by an albumin-Cre transgene occurs progressively with age. Genesis 26(2):149-150.
36. Srinivas S, et al. (2001) Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol 1:4.
37. Germain L, Blouin MJ, Marceau N (1988) Biliary epithelial and hepatocytic cell lineage relationships in embryonic rat liver as determined by the differential expression of cytokeratins, alpha-fetoprotein, albumin, and cell surface-exposed components. Cancer Res 48(17):4909-4918.
38. Bird TG, Lorenzini S, Forbes SJ (2008) Activation of stem cells in hepatic diseases. Cell Tissue Res 331(1):283-300.
39. Kuwahara R, et al. (2008) The hepatic stem cell niche: Identification by label-retaining cell assay. Hepatology 47(6):1994-2002.
40. Hirabayashi S, et al. (2008) Threonine 74 of MOB1 is a putative key phosphorylation site by MST2 to form the scaffold to activate nuclear Dbf2-related kinase 1. Oncogene 27(31):4281-4292.
41. Sekiya S, Suzuki A (2014) Hepatocytes, rather than cholangiocytes, can be the major source of primitive ductules in the chronically injured mouse liver. Am J Pathol 184(5): 1468-1478.
42. Takayama K, et al. (2014) CCAAT/enhancer binding protein-mediated regulation of TGFβ receptor 2 expression determines the hepatoblast fate decision. Development 141(1):91-100.
43. Ma Y, Yang Y, Wang F, Wei Q, Qin H (2015) Hippo-YAP signaling pathway: A new paradigm for cancer therapy. Int J Cancer 137(10):2275-2286.
44. Traore MO, et al. (2012) Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: Final results of a study in Mali and Senegal. Plos Neglect Trop D 6(9):e1825.
45. Wang CC, Pong SS (1982) Actions of avermectin B1a on GABA nerves. Prog Clin Biol Res 97:373-395.
46. Akkari L, et al. (2010) Cell shape and TGF-beta signaling define the choice of lineage during in vitro differentiation of mouse primary hepatic precursors. J Cell Physiol 225(1):186-195.
47. Wang X, et al. (2014) Osteopontin induces ductular reaction contributing to liver fibrosis. Gut 63(11):1805-1818.
48. Chen Q, et al. (2015) Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP. Genes Dev 29(12):1285-1297.
49. Dadarkar SS, Deore MD, Gatne MM (2007) Comparative evaluation of acute toxicity of ivermectin by two methods after single subcutaneous administration in rats. Regul Toxicol Pharmacol 47(3):257-260.
50. Sharmeen S, et al. (2010) The antiparasitic agent ivermectin induces chloridedependent membrane hyperpolarization and cell death in leukemia cells. Blood 116(18): 3593-3603.
51. Melotti A, et al. (2014) The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. EMBO Mol Med 6(10): 1263-1278.
52. Hashimoto H, Messerli SM, Sudo T, Maruta H (2009) Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines. Drug Discov Ther 3(6):243-246.
53. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA (2012) Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J 443(3):851-856.
54. Schuler M, Dierich A, Chambon P, Metzger D (2004) Efficient temporally controlled targeted somatic mutagenesis in hepatocytes of the mouse. Genesis 39(3):167-172.
55. Badea TC, Wang Y, Nathans J (2003) A noninvasive genetic/pharmacologic strategy for visualizing cell morphology and clonal relationships in the mouse. J Neurosci 23(6): 2314-2322.
56. Makita R, et al. (2008) Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. Am J Physiol Renal Physiol 294(3):F542-F553.
57. Cazac BB, Roes J (2000) TGF-beta receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 13(4):443-451.
58. Liu S, Shi-wen X, Abraham DJ, Leask A (2011) CCN2 is required for bleomycin-induced skin fibrosis in mice. Arthritis Rheum 63(1):239-246.
59. National Academy of Sciences (2011) Guide for the Care and Use of Laboratory Animals (National Academies, Washington, DC), 8th Ed.
60. Suzuki A, et al. (1997) Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev 11(10):1242-1252.
61. Nishikawa Y, et al. (2005) Transdifferentiation of mature rat hepatocytes into bile duct-like cells in vitro. Am J Pathol 166(4):1077-1088.
62. Engelhardt NV, et al. (1990) Common antigens of mouse oval and biliary epithelial cells. Expression on newly formed hepatocytes. Differentiation 45(1):29-37.
63. Sone M, et al. (2012) Recovery of mature hepatocytic phenotype following bile ductular transdifferentiation of rat hepatocytes in vitro. Am J Pathol 181(6):2094-2104.
64. Murakami H, et al. (2011) LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res 71(3):873-883.